Simone Mester
- Researcher; PhD
Publications 2024
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Nat Commun, 15 (1), 2007
DOI 10.1038/s41467-024-46321-9, PubMed 38453922
Publications 2023
Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties
Int J Retina Vitreous, 9 (1), 65
DOI 10.1186/s40942-023-00507-3, PubMed 37936232
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
Front Immunol, 14, 1178817
DOI 10.3389/fimmu.2023.1178817, PubMed 37346044
Publications 2022
Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
Commun Biol, 5 (1), 832
DOI 10.1038/s42003-022-03787-x, PubMed 35982144
A Silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics
Front Ophthalmol (Lausanne), 2, 882013
DOI 10.3389/fopht.2022.882013, PubMed 38983507
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
iScience, 25 (2), 103746
DOI 10.1016/j.isci.2022.103746, PubMed 35118359
Publications 2021
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196